Supply Chain Intelligence

Gyre Therapeutics, Inc. Supply Chain

GYRE supply chain intelligence for Gyre Therapeutics, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

GYRE ·Last updated 2026-07-29 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

1Suppliers
18Customers
3Debt Items
20Related Chains

Gyre Therapeutics, Inc. Suppliers

TickerNameConfidenceEvidence
CULLGEN-INC CULLGEN-INC 90% Agreement and Plan of Merger and Reorganization, dated March 2, 2026, by and among Gyre Therapeutics, Inc., Helix Merger Sub Corp., and Cullgen Inc.

Gyre Therapeutics, Inc. Customers

TickerNameConfidenceEvidence
SINOPHARM-GROUP-CO-LTD SINOPHARM-GROUP-CO-LTD 95% For the three months ended March 31, 2026, the Company had three customers, Sinopharm Group Co., Ltd. ("Sinopharm"), China Resources Pharmaceutical Group Ltd. ("Resources Pharmaceutical"), and Shangh…
CHINA-RESOURCES-PHARMACEUTICAL-GROUP-LTD CHINA-RESOURCES-PHARMACEUTICAL-GROUP-LTD 90% For the three months ended March 31, 2026, the Company had three customers, Sinopharm Group Co., Ltd. ("Sinopharm"), China Resources Pharmaceutical Group Ltd. ("Resources Pharmaceutical"), and Shangh…
SHANGHAI-PHARMACEUTICALS-HOLDING-CO-LTD SHANGHAI-PHARMACEUTICALS-HOLDING-CO-LTD 90% For the three months ended March 31, 2026, the Company had three customers, Sinopharm Group Co., Ltd. ("Sinopharm"), China Resources Pharmaceutical Group Ltd. ("Resources Pharmaceutical"), and Shangh…
SINOPHARM-GROUP-CO-LTD-CHINA-RESOURCES-PHARMACEU SINOPHARM-GROUP-CO-LTD-CHINA-RESOURCES-PHARMACEU 85% . Historically, the Company has collected receivables from customers within the credit terms with no significant credit losses incurred. Note receivable is also subject to credit risk. The Company mo…
GALT Galectin Therapeutics Inc. 72% Reciprocal relationship from GALT graph: Reciprocal relationship from GYRE graph: Reciprocal relationship from GALT graph: Reciprocal relationship from GYRE graph: Reciprocal relationship from GALT g…
GALT Galectin Therapeutics Inc. 72% associated with chronic liver disease (“CLD”) and chronic idiopathic thrombocytopenia (“ITP”). Other Product Candidates F573 is our clinical-stage product candidate for the treatment of acute/acute-o…
GLMD Galmed Pharmaceuticals Ltd. 72% Reciprocal relationship from GLMD graph: Reciprocal relationship from GYRE graph: associated with chronic liver disease (“CLD”) and chronic idiopathic thrombocytopenia (“ITP”). Other Product Candidat…
GLMD Galmed Pharmaceuticals Ltd. 72% associated with chronic liver disease (“CLD”) and chronic idiopathic thrombocytopenia (“ITP”). Other Product Candidates F573 is our clinical-stage product candidate for the treatment of acute/acute-o…
LLY Eli Lilly and Company 72% associated with chronic liver disease (“CLD”) and chronic idiopathic thrombocytopenia (“ITP”). Other Product Candidates F573 is our clinical-stage product candidate for the treatment of acute/acute-o…
LLY Eli Lilly and Company 72% Reciprocal relationship from LLY graph: Reciprocal relationship from GYRE graph: associated with chronic liver disease (“CLD”) and chronic idiopathic thrombocytopenia (“ITP”). Other Product Candidate…
MDGL Madrigal Pharmaceuticals, Inc. 72% associated with chronic liver disease (“CLD”) and chronic idiopathic thrombocytopenia (“ITP”). Other Product Candidates F573 is our clinical-stage product candidate for the treatment of acute/acute-o…
MDGL Madrigal Pharmaceuticals, Inc. 72% Reciprocal relationship from MDGL graph: Reciprocal relationship from GYRE graph: associated with chronic liver disease (“CLD”) and chronic idiopathic thrombocytopenia (“ITP”). Other Product Candidat…
MRK Merck & Co., Inc. 72% associated with chronic liver disease (“CLD”) and chronic idiopathic thrombocytopenia (“ITP”). Other Product Candidates F573 is our clinical-stage product candidate for the treatment of acute/acute-o…
MRK Merck & Co., Inc. 72% Reciprocal relationship from MRK graph: Reciprocal relationship from GYRE graph: Reciprocal relationship from MRK graph: Reciprocal relationship from GYRE graph: Reciprocal relationship from MRK grap…
NVO Novo Nordisk A/S 72% Reciprocal relationship from NVO graph: Reciprocal relationship from GYRE graph: associated with chronic liver disease (“CLD”) and chronic idiopathic thrombocytopenia (“ITP”). Other Product Candidate…
NVO Novo Nordisk A/S 72% associated with chronic liver disease (“CLD”) and chronic idiopathic thrombocytopenia (“ITP”). Other Product Candidates F573 is our clinical-stage product candidate for the treatment of acute/acute-o…
VKTX Viking Therapeutics, Inc. 72% associated with chronic liver disease (“CLD”) and chronic idiopathic thrombocytopenia (“ITP”). Other Product Candidates F573 is our clinical-stage product candidate for the treatment of acute/acute-o…
VKTX Viking Therapeutics, Inc. 72% Reciprocal relationship from VKTX graph: Reciprocal relationship from GYRE graph: Reciprocal relationship from VKTX graph: Reciprocal relationship from GYRE graph: Reciprocal relationship from VKTX g…

Gyre Therapeutics, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
GYRE-DEBT-9965 Xbrl Convertible 90% xbrl convertible detail from xbrl 2018-12-31.
GYRE-DEBT-9964 Warrants outstanding: 2070000 90% xbrl warrant detail from xbrl 2026-03-31.
GYRE-DEBT Debt stack $823,000 90% Market cache reports total debt of $823,000.

Gyre Therapeutics, Inc. Acquisitions

Acquired EntityNameConfidenceEvidence
GYRE-ACQ-0001140361-26-007249 Gyre Therapeutics will acquire Cullgen in an all-stock transaction valuing Cullgen at approximat... 85% Gyre Therapeutics will acquire Cullgen in an all-stock transaction valuing Cullgen at approximately $300 million.
GYRE-ACQ-0001140361-26-018716 Gyre Therapeutics acquired Cullgen in an all-stock transaction valued at approximately $300 mill... 85% Gyre Therapeutics acquired Cullgen in an all-stock transaction valued at approximately $300 million.

Gyre Therapeutics, Inc. Ownership

HolderNameConfidenceEvidence
GYRE-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC VANGUARD CAPITAL MANAGEMENT LLC 90% 13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 57 tracked holders.

Gyre Therapeutics, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
NVO Novo Nordisk A/S 100.00 1 ['customer']
GLMD Galmed Pharmaceuticals Ltd. 100.00 1 ['customer']
LLY Eli Lilly and Company 100.00 1 ['customer']
GALT Galectin Therapeutics Inc. 100.00 1 ['customer']
MDGL Madrigal Pharmaceuticals, Inc. 100.00 1 ['customer']
MRK Merck & Co., Inc. 100.00 1 ['customer']
VKTX Viking Therapeutics, Inc. 100.00 1 ['customer']
CRBP Corbus Pharmaceuticals Holdings, Inc. 50.00 2
EXOZ eXoZymes, Inc. 50.00 2
CTNM Contineum Therapeutics, Inc. 50.00 2
IMMP Immutep Limited 50.00 2
BIOA BioAge Labs, Inc. 50.00 2
CYTK Cytokinetics, Incorporated 50.00 2
FHTX Foghorn Therapeutics Inc. 50.00 2
AVIR Atea Pharmaceuticals, Inc. 50.00 2
DKS DICK'S Sporting Goods, Inc. 50.00 2
AXSM Axsome Therapeutics, Inc. 50.00 2
PSNL Personalis, Inc. 50.00 2
AKTS Aktis Oncology, Inc. 50.00 2
DSGN Design Therapeutics, Inc. 50.00 2
View GYRE supply chain intel →

Explore the full interactive supply chain map for Gyre Therapeutics, Inc..

Open GYRE supply chain map →
ChainSifter · Guerilla Finance Terms Disclaimer ← Back to Map